banner news

Singapore, July 29, 2019 – Credo Biomedical Pte. Ltd., a groundbreaking point-of-care rapid molecular diagnostic company, announced today they will introduce their new molecular diagnostic platform, VitaPCR, and its Influenza A/B assay, at the 71st AACC Clinical Expo that will take place in Anaheim on 6th, 7th, and 8th August 2019.

 

Based on real-time polymerase chain reaction (real-time PCR), VitaPCR Influenza A/B is a true point-of-care platform that combines ease of use, speed and affordability. It delivers lab- accurate results in less than 20 minutes with only 2 minutes hand-on time at the same price level as traditional lateral flow tests.

 

According to the World Health Organization, there are on average 600 million to 1.2 billion global seasonal influenza cases per year with 3 million to 5 million cases categorized as severe and 500,000 to 1,000,000 cases resulting in death. In the USA alone, the burden is estimated to be around USD 80 billion.


The current solution to contain an influenza outbreak relies on the Rapid Influenza Diagnostic Tests (RIDTs) for screening. However, according to the CDC, RIDTs have a sensitivity ranging from 50 to 70%. Companies have developed Point-of-Care molecular diagnostic solutions for influenza, some with funding support from the government and NGO; however, these solutions are usually 3 to 4 times more expensive than RIDTs to the patients, making it inaccessible to the masses.

Combining speed, accuracy, and ease-of-use required for any advanced POC molecular diagnostic platform, VitaPCR Influenza A/B delivers rapid and actionable results for the same price level as RIDTs, making molecular diagnostic tools highly accessible to patients and affordable to all.


“There is a clear need for early diagnostic for influenza as treatment is most effective in the first 48hrs of symptom onset. Point of Care molecular solution is the best option for optimal patient care outcome.” said Stephen Kao, CEO of Credo Biomedical. “Credo’s solution is based on proven science with special care in ease-of-use and unprecedented affordability. This affordability will make our solution accessible to the masses to help combat influenza”.

 

Credo Biomedical will be located at the booth #4339, where it will be meeting with practitioners, researchers, and potential business partners, and perform live demonstration of its Influenza A/B assay.

 


About Credo Biomedical Pte. Ltd.

Credo Biomedical develops, and manufactures innovative, cost-effective, and rapid Molecular Diagnostic solutions at the Point-of-Care (POC) in the areas of Animal Health, Human Health, and Human Wellness. By providing the right information, at the right time, and to the right people, we can improve the lives of billions of people and animals around the world.

 

CONTACT

We at Credo pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.